Add this topic to your myFT Digest for news straight to your inbox
Older inactivated virus technology in domestic shots less effective against infection than foreign rivals
Hong Kong researchers say two doses of the jab provided ‘insufficient’ antibodies against new variant
Despite dispensing 2.5bn doses, recent outbreaks raise uncertainty over Sinovac and Sinopharm jabs
Officials insist jabs work but lack of peer-reviewed research reinforces doubts about efficacy
Top health official says remarks about jabs were ‘taken out of context’
Disease control centre makes first public admission over effectiveness of domestic jabs
Beijing offers smoother entry procedures to visitors who take locally made jabs
Concerns over transparency, efficacy and supply weaken global demand for country’s Covid-19 jabs
International travel restrictions expected until next year
Group will travel to mainland China as wider inoculation rollout delayed in territory
Demand for Sinovac’s CoronaVac will remain high. In most developing countries, it is the only option
Vaccination programme begins after green light from health regulator
Beijing-backed jab faces greater scrutiny after Brazil trial confusion
With Covid-19 cases rocketing, Jakarta bets on inoculating 180m citizens across 10,000 islands
Shot developed by Sinovac is key to Beijing’s ambitions to send vaccinations around the world
For now, Sino Biopharm is the only way to buy exposure to upside from CoronaVac sales
Sinovac looks to increase production and distribution worldwide after trailing western rivals
International Edition